MedTrace Logo

COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1

NCT04356508 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-04-22

No results posted yet for this study

Summary

This is an open-label, controlled, single-centre pilot study of nivolumab in adult patients with COVID-19. This clinical study aims to evaluate efficacy of anti-PD1 antibody in relation to viral clearance and its safety.

Conditions

Interventions

DRUG

Nivolumab

Single dose at 0.3mg/kg

Sponsors & Collaborators

  • The University of Hong Kong

    collaborator OTHER

  • Dr Gerry Gin Wai Kwok

    lead OTHER

Principal Investigators

  • Gerry Gin Wai Kwok, MBBS · Queen Mary Hospital, Hong Kong

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-14
Primary Completion
2020-06-30
Completion
2021-08-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04356508 on ClinicalTrials.gov